Akebia Therapeutics logo
Akebia Therapeutics AKBA
$ 1.41 -1.4%

Annual report 2025
added 02-26-2026

report update icon

Akebia Therapeutics Financial Statements 2011-2026 | AKBA

Annual Financial Statements Akebia Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

334 M 274 M 257 M 141 M 358 M 479 M 892 M 669 M 653 M 370 M 194 M 158 M - - -

Shares

257 M 211 M 187 M 183 M 166 M 138 M 118 M 117 M 43.5 M 37.7 M 26.5 M 15.4 M - - -

Historical Prices

1.3 1.3 1.37 0.77 2.16 3.46 8.87 7.28 14.3 10 7.3 9.26 - - -

Net Income

-5.34 M -69.4 M -51.9 M -94.2 M -282 M -385 M -280 M -144 M -76.9 M -136 M -60.7 M -37 M -13.2 M -8.2 M -

Revenue

236 M 160 M 195 M 292 M 212 M 295 M 335 M 208 M 178 M 1.54 M - - - - -

Cost of Revenue

39.5 M 63.2 M 74.1 M 85.6 M 151 M 296 M 145 M 7.77 M - - - - - - -

Gross Profit

- - - - - - 190 M 200 M - - - - - - -

Operating Income

23.5 M -50.5 M -46.3 M -80.8 M -265 M -378 M -286 M -178 M -76.7 M -136 M -61.5 M -37.9 M -15.9 M -8.52 M -

Interest Expense

58 K 94 K 887 K 3.15 M 2.41 M 1.86 M -794 K 81 K 204 K -188 K 287 K 700 K -704 K -1.64 M -

EBITDA

24.8 M -49 M -44.7 M -79.1 M -263 M -376 M -248 M -176 M -79.3 M -136 M -61.4 M -37.9 M -14.9 M -8.52 M -

Operating Expenses

173 M 147 M 167 M 288 M 325 M 376 M 476 M 378 M 258 M 138 M 61.5 M 37.9 M - - -

General and Administrative Expenses

107 M 107 M 100 M 139 M 174 M 154 M 149 M 87.1 M 27 M 22.2 M 18.5 M 12.5 M 5.15 M 2.89 M -

All numbers in USD currency

Quarterly Income Statement Akebia Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

265 M 263 M 235 M 225 M 210 M 210 M 205 M 195 M 188 M 187 M 185 M 184 M 184 M 184 M 180 M 177 M 174 M 161 M 154 M 145 M 143 M 137 M 128 M 119 M 119 M 118 M 117 M 69.4 M 57 M 56.9 M 48.6 M 47.4 M 46.9 M 40.8 M 38.8 M 38.6 M 37.9 M 37.8 M 36.9 M 30.7 M 28.8 M 26.6 M 20 M 20.4 M 19.7 M 19.7 M 2.23 M 1.38 M 547 K 505 K 476 K - - - - - - - -

Net Income

540 K 247 K 6.11 M - -20 M -8.58 M -18 M - -14.5 M -11.2 M -26.2 M - -54.1 M 29.4 M -62.4 M - -59.5 M -83 M -69.6 M -87 M -60 M -176 M -60.7 M -94.5 M -54.6 M -58.2 M -72.4 M -60.1 M -26 M -34.1 M -60.1 M 15.5 M -23.1 M -21.5 M -44.5 M -37.9 M -36.3 M -35.8 M -25.8 M -19.9 M -19.5 M -10.7 M -10.7 M -10.4 M -9.35 M -7.62 M -9.7 M -5.95 M -3.77 M -2.83 M -621 K - - - - - - - -

Revenue

58.8 M 62.5 M 57.3 M - 37.4 M 43.6 M 32.6 M - 42 M 56.4 M 40.1 M - 48.7 M 126 M 61.7 M - 48.8 M 52.9 M 52.3 M - 60 M 90.1 M 88.5 M - 92 M 101 M 72.7 M - 53.2 M 48.8 M 45.9 M - 41.3 M 28.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

9.38 M 9.92 M 7.62 M - 14.2 M 17 M 11.6 M - 18 M 17.3 M 19.5 M - 38.3 M 18.6 M 31.3 M - 15.9 M 52.5 M 34.6 M 63.2 M 30.3 M 175 M 27.7 M 38.1 M 38.3 M 37.7 M 31.3 M 7.77 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

4.45 M 14.1 M 13.5 M - -12.5 M -8.72 M -14.9 M - -13 M -9 M -24.9 M - -50.4 M 34.1 M -58.5 M - -54.9 M -79.3 M -64.9 M -85.4 M -58.1 M -174 M -59.1 M -94.9 M -55.9 M -59.5 M -76 M -90.2 M -27.8 M -35.7 M -24.5 M 14.6 M -24.2 M -22.1 M -45 M -38 M -36.2 M -36.2 M -26 M -20 M -19.7 M -10.9 M -10.9 M -10.6 M -9.58 M -7.84 M -9.91 M -6.2 M -4.03 M -3.12 M -2.58 M - - - - - - - -

Interest Expense

-10 K -28 K 213 K - -17 K -39 K 95 K - -43 K -10 K 282 K - 1.17 M 411 K 1.13 M - 427 K 1.26 M 161 K - 410 K 376 K 350 K - -185 K 23 K -78 K - 16 K 32 K 4 K - 200 K 10 K -6 K - -345 K 139 K 14 K - 64 K 116 K 96 K - 56 K 51 K 19 K - 28 K 2.91 K -754 K - - - - - - - -

EBITDA

- - 13.8 M - -3.5 M 275 K -14.6 M - -4.04 M 4 K -15.9 M - -41.4 M 43.1 M -49.5 M - -45.9 M -70.3 M -55.9 M -85.4 M -57.6 M -173 M -58.6 M -94.9 M -55.3 M -58.9 M -75.5 M -90.2 M -27.2 M -35.2 M -24.3 M 14.6 M -23.8 M -21.9 M -44.8 M -38 M -36 M -36.1 M -26 M -20 M -19.6 M -10.8 M -10.9 M -10.6 M -9.57 M -7.83 M -9.9 M -6.2 M -4.03 M -3.12 M -2.58 M - - - - - - - -

Operating Expenses

44.9 M 38.5 M 36.2 M - 35.8 M 35.3 M 35.9 M - 37.1 M 48.1 M 45.6 M - 60.8 M 73.7 M 88.8 M - 87.7 M 79.8 M 82.6 M 78.9 M 87.7 M 89.3 M 120 M 126 M 110 M 123 M 117 M 142 M 81 M 84.5 M 70.4 M 75.9 M 65.5 M 50.7 M 65.8 M 39.6 M 36.2 M 36.2 M 26 M 20 M 19.7 M 10.9 M 10.9 M 10.6 M 9.58 M 7.84 M 9.91 M 6.2 M 4.03 M 3.12 M 2.58 M - - - - - - - -

General and Administrative Expenses

29.1 M 26.6 M 25.7 M - 26.5 M 26.9 M 25.4 M - 22.7 M 27 M 25.2 M - 31.9 M 32.2 M 44.3 M - 46.4 M 41.7 M 41.3 M - 40.2 M 35.5 M 38 M - 34.2 M 36.1 M 34.3 M - 10.4 M 12.5 M 9.02 M - 6.75 M 6.9 M 5.79 M - 4.94 M 5.31 M 5.81 M - 4.07 M 4.38 M 4.23 M - 2.94 M 2.32 M 3.75 M - 794 K 668 K 679 K - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Akebia Therapeutics AKBA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Akebia Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.57 0.04 % $ 3.74 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.98 -0.11 % $ 27.2 B germanyGermany
Aytu BioScience Aytu BioScience
AYTU
$ 2.56 -3.76 % $ 16.1 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.85 -1.39 % $ 9.26 B australiaAustralia
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.87 2.3 % $ 976 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.17 -0.24 % $ 446 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.57 -0.16 % $ 3.13 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.17 2.59 % $ 319 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.93 -4.87 % $ 6.38 B israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 33.62 3.73 % $ 2.23 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.92 1.03 % $ 264 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA